Type of information: Nomination
Compound: senior vice president
Company: Editas Medicine (USa - MA)
Therapeutic area: Rare diseases - Genetic diseases - Ophtalmological diseases
Type agreement: nomination
- • On October 1, 2018, Editas Medicine announced that Richard A. Morgan, a leading expert in gene therapy and oncology, joins the company as senior vice president of Immunogenetics. Dr. Morgan brings to Editas Medicine more than 30 years of scientific leadership in the life sciences industry and at federal research agencies including the National Institutes of Health (NIH). He most recently served as Vice President, Immunotherapy, at bluebird bio. While at bluebird bio, Dr. Morgan’s team developed the company’s lead oncology asset bb2121, an investigational anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy for the treatment of multiple myeloma. Prior to his position at bluebird bio, Dr. Morgan was a Staff Scientist for the Surgery Branch of the National Cancer Institute and the Interim Chief of the Clinical Gene Therapy Branch of the National Human Genome Research Institute. Dr. Morgan is a member of the board of directors of the American Society of Gene and Cell Therapy (ASGCT), serving as the translational and clinical development representative, and he has published more than 150 scientific papers during his career. He received his Ph.D. in genetics from John Hopkins University and his B.A. in biochemistry from Brandeis University.
- In addition, Editas Medicine named X. Kate Zhang, as Vice President of Biological Development. Dr. Zhang brings more than two decades of translational science and early- and late-stage biological therapeutic development to the Company.
- Dr. Zhang joins Editas Medicine from Sanofi S.A. (and Genzyme prior to its acquisition by Sanofi), where she held several leadership positions across research and development organizations, recently as Senior Director of global translational science and of biological pharmaceutical development. During her career, Dr. Zhang worked with and led multi-disciplinary teams for the successful development and commercial launch of multiple biologic drugs. Dr. Zhang received her Ph.D. in analytical chemistry from Queen’s University in Ontario, Canada, and completed a post-doctoral fellowship at the National Institutes of Health’s National Heart, Lung, and Blood Institute. She received her B.Eng. from Tsinghua University in China.